Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Revenue declinedNet loss reportedExceptional itemEBITDA margin compressionResults View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹204.50

prior close

₹197.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.9%-0.2% vs market

Pharmaceuticals peers, median of 149sector+0.8%-0.1% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-1.3

15m

+1.2

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8+0.9-0.2+0.8-0.1

Next day

-1.6+0.8-2.4+0.9-2.5

-3.7-0.1-3.6+0.0-3.7

-6.8-1.7-5.1-2.1-4.8

-4.5-0.8-3.8-1.4-3.2

-5.4-1.1-4.3-2.0-3.4

-5.8-2.4-3.4-3.3-2.4

15d

-6.1-0.6-5.5-3.1-3.0

-10.4-3.8-6.6-5.2-5.2

-6.2-2.9-3.3-5.7-0.4

-0.2+1.5-1.8-5.2+5.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma reported its Q1 FY26 results, with standalone revenue from operations at Rs. 969.88 crores, down about 8.8% from Rs. 1,063.20 crores in the same quarter last year. Despite the revenue dip, standalone net profit rose roughly 33% YoY to Rs. 113.14 crores (vs Rs. 85.27 crores), helped by a sharp jump in other income to Rs. 180.92 crores. Standalone EPS stood at Rs. 0.85 versus Rs. 0.64 a year ago. On a consolidated basis, revenue was nearly flat at Rs. 1,933.71 crores, but the company slipped to a net loss of Rs. 81.70 crores (vs Rs. 88.64 cr loss in Q1 FY25). A Rs. 20.74 crore exceptional gain from a settlement in the IBC proceedings of a supplier to its critical care subsidiary cushioned the consolidated loss. The results carry a clean limited review report from Deloitte Haskins & Sells LLP.

Likely market impact

Mixed picture for shareholders – standalone profits look healthier year-on-year, largely driven by non-operating income, while the consolidated business continues to report losses, though slightly narrower than last year. The stock reaction may depend on how investors weigh the one-time other-income boost versus the persistent consolidated loss.

By the numbersConsolidated · Q1 FY26 vs Q1 FY25

	Q1 FY26	Q1 FY25	Change
Revenue	₹1,934 Cr	₹1,951 Cr	−0.9%
Operating profit	−₹176.7 Cr	−₹87.02 Cr	loss widened
Profit after tax	−₹81.70 Cr	−₹88.64 Cr	loss narrowed
EBITDA margin	6.6%	10.5%	−3.9 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.